Patient and treatment characteristics
| Characteristic . | N (%) . | P . | ||
|---|---|---|---|---|
| All patients . | MD Anderson group . | Dana-Farber group . | ||
| All patients | ||||
| Total | 65 | 49 | 16 | |
| Age, y | ||||
| Median | 35 | 36 | 34.5 | |
| Range | 19-65 | 19-65 | 21-55 | |
| Female sex | 34 (52) | 26 (53) | 8 (50) | .831 |
| Disease stage | .011 | |||
| I | 24 (37) | 19 (39) | 5 (31) | |
| II | 32 (49) | 27 (55) | 5 (31) | |
| III | 4 (6) | 2 (4) | 2 (12) | |
| IV | 5 (8) | 1 (2) | 4 (25) | |
| B symptoms | 17 (26) | 15 (31) | 2 (12) | .152 |
| Performance status | .001 | |||
| 0-1 | 63 (97) | 47 (96) | 16 (100) | |
| 2 | 2 (3) | 2 (4) | ||
| Bulky disease | ||||
| Median axial dimension, cm | 10.8 | 10.6 | 11.3 | .325 |
| Range | 4-18 | 4-18 | 6-18 | |
| Maximum axial dimension ≥10 cm | 43 (66) | 29 (59) | 14 (87) | .038 |
| Serum LDH, IU/L | .880 | |||
| >ULN | 41 (63) | 31 (63) | 10 (62) | |
| IPI score | .005 | |||
| 0 | 22 (34) | 17 (35) | 5 (31) | |
| 1 | 33 (51) | 28 (57) | 5 (31) | |
| 2 | 5 (8) | 3 (6) | 2 (12) | |
| 3 | 4 (6) | 0 | 4 (25) | |
| Unknown | 1 (1) | 1 (2) | ||
| DA-R-EPOCH | .333 | |||
| N of cycles | ||||
| Median | 6 | 6 | 6 | |
| Range | 4-7 | 4-7 | 4-6 | |
| 6 cycles | 62 (95) | 47 (96) | 15 (94) | |
| RT | 13 (20) | 10 (20) | 3 (19) | .886 |
| Consolidative | 3 (5) | 2 (4) | 1 (6) | |
| Salvage | 10 (15) | 8 (16) | 2 (12) | |
| Dose, Gy | ||||
| Median | 42 | 39.6 | 42 | .336 |
| Range | 30-49 | 30.6-49 | 30-44 | |
| Salvage chemotherapy | 10 (15) | 8 (16) | 2 (12) | .650 |
| SCT | 10 (15) | 8 (16) | 2 (12) | .713 |
| Autologous | 6 (9) | 4 (8) | 2 (12) | |
| Allogeneic | 4 (6) | 4 (8) | ||
| Follow-up time, mo | .0003 | |||
| Median | 36.6 | 41.2 | 25.7 | |
| 95% CI | 28.1-45.1 | 35.6-46.9 | 22.4-29.0 | |
| Patients undergoing salvage therapy | ||||
| Total | 12 | 10 | 2 | |
| Age, y | ||||
| Median | 34 | 34.5 | 28.5 | |
| Range | 21-50 | 21-50 | 22-35 | |
| Female sex | 4 (33) | 4 (40) | 0 | |
| Bulky disease >10 cm | 11 (92) | 9 (90) | 2 (100) | |
| Biopsy findings | ||||
| Positive | 6 (50) | 6 (60) | ||
| Not done | 6 (50) | 4 (40) | 2 (100) | |
| Salvage chemotherapy | 10 (83) | 8 (80) | 2 (100) | |
| Salvage RT | 10 (83) | 8 (80) | 2 (100) | |
| Dose, Gy | ||||
| Median | 43.6 | 43.6 | 42 | |
| Range | 31-49 | 31-49 | 40-44 | |
| SCT | 10 (83) | 8 (80) | 2 (100) | |
| Autologous | 6 (50) | 4 (50) | 2 (100) | |
| Allogeneic | 4 (33) | 4 (50) | ||
| Characteristic . | N (%) . | P . | ||
|---|---|---|---|---|
| All patients . | MD Anderson group . | Dana-Farber group . | ||
| All patients | ||||
| Total | 65 | 49 | 16 | |
| Age, y | ||||
| Median | 35 | 36 | 34.5 | |
| Range | 19-65 | 19-65 | 21-55 | |
| Female sex | 34 (52) | 26 (53) | 8 (50) | .831 |
| Disease stage | .011 | |||
| I | 24 (37) | 19 (39) | 5 (31) | |
| II | 32 (49) | 27 (55) | 5 (31) | |
| III | 4 (6) | 2 (4) | 2 (12) | |
| IV | 5 (8) | 1 (2) | 4 (25) | |
| B symptoms | 17 (26) | 15 (31) | 2 (12) | .152 |
| Performance status | .001 | |||
| 0-1 | 63 (97) | 47 (96) | 16 (100) | |
| 2 | 2 (3) | 2 (4) | ||
| Bulky disease | ||||
| Median axial dimension, cm | 10.8 | 10.6 | 11.3 | .325 |
| Range | 4-18 | 4-18 | 6-18 | |
| Maximum axial dimension ≥10 cm | 43 (66) | 29 (59) | 14 (87) | .038 |
| Serum LDH, IU/L | .880 | |||
| >ULN | 41 (63) | 31 (63) | 10 (62) | |
| IPI score | .005 | |||
| 0 | 22 (34) | 17 (35) | 5 (31) | |
| 1 | 33 (51) | 28 (57) | 5 (31) | |
| 2 | 5 (8) | 3 (6) | 2 (12) | |
| 3 | 4 (6) | 0 | 4 (25) | |
| Unknown | 1 (1) | 1 (2) | ||
| DA-R-EPOCH | .333 | |||
| N of cycles | ||||
| Median | 6 | 6 | 6 | |
| Range | 4-7 | 4-7 | 4-6 | |
| 6 cycles | 62 (95) | 47 (96) | 15 (94) | |
| RT | 13 (20) | 10 (20) | 3 (19) | .886 |
| Consolidative | 3 (5) | 2 (4) | 1 (6) | |
| Salvage | 10 (15) | 8 (16) | 2 (12) | |
| Dose, Gy | ||||
| Median | 42 | 39.6 | 42 | .336 |
| Range | 30-49 | 30.6-49 | 30-44 | |
| Salvage chemotherapy | 10 (15) | 8 (16) | 2 (12) | .650 |
| SCT | 10 (15) | 8 (16) | 2 (12) | .713 |
| Autologous | 6 (9) | 4 (8) | 2 (12) | |
| Allogeneic | 4 (6) | 4 (8) | ||
| Follow-up time, mo | .0003 | |||
| Median | 36.6 | 41.2 | 25.7 | |
| 95% CI | 28.1-45.1 | 35.6-46.9 | 22.4-29.0 | |
| Patients undergoing salvage therapy | ||||
| Total | 12 | 10 | 2 | |
| Age, y | ||||
| Median | 34 | 34.5 | 28.5 | |
| Range | 21-50 | 21-50 | 22-35 | |
| Female sex | 4 (33) | 4 (40) | 0 | |
| Bulky disease >10 cm | 11 (92) | 9 (90) | 2 (100) | |
| Biopsy findings | ||||
| Positive | 6 (50) | 6 (60) | ||
| Not done | 6 (50) | 4 (40) | 2 (100) | |
| Salvage chemotherapy | 10 (83) | 8 (80) | 2 (100) | |
| Salvage RT | 10 (83) | 8 (80) | 2 (100) | |
| Dose, Gy | ||||
| Median | 43.6 | 43.6 | 42 | |
| Range | 31-49 | 31-49 | 40-44 | |
| SCT | 10 (83) | 8 (80) | 2 (100) | |
| Autologous | 6 (50) | 4 (50) | 2 (100) | |
| Allogeneic | 4 (33) | 4 (50) | ||
LDH, lactate dehydrogenase; ULN, upper limit of normal.